The role of mediastinal adipose tissue 11β-hydroxysteroid d ehydrogenase type 1 and glucocorticoid expression in the development of coronary atherosclerosis in obese patients with ischemic heart disease

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Atalar, Fatmahan ^a   Gormez, Selcuk ^b   Caynak, Baris ^c   Akan, Gokce ^c   Tanriverdi, Gamze ^d   Bilgic Gazioglu, Sema ^d   Gunay, Demet ^e   Duran, Cihan ^c   Akpinar, Belhhan ^c   Ozbek, Ugur ^d   Buyukdevrim, Ahmet S ^f   Yazici, Zeliha ^d  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ACIBADEM HOSPITAL   (Turkey)

^c ISTANBUL BILIM UNIVERSITY   (Turkey)

^d ISTANBUL UNIVERSITY   (Turkey)

^e FLORENCE NIGHTINGALE HOSPITAL   (Turkey)

^f ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Coronary artery disease; Cortisol; Glucocorticoid; Inflammation; Mediastinal adipose tissue; Stearidonic acid

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; ARACHIDONIC ACID; CD68 ANTIGEN; FATTY ACID; GLUCOCORTICOID; STEARIDONIC ACID;

ADIPOSE TISSUE; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; EPICARDIUM; FEMALE; HEART VALVE SURGERY; HUMAN; ISCHEMIC HEART DISEASE; MALE; MEDIASTINUM; OBESITY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SUBCUTANEOUS FAT;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ARACHIDONIC ACID; CASE-CONTROL STUDIES; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYDROCORTISONE; INTRA-ABDOMINAL FAT; LINEAR MODELS; MALE; MEDIASTINUM; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; OBESITY; RECEPTORS, GLUCOCORTICOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUBCUTANEOUS FAT;

EID: 84866551680     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-115     Document Type: Article

References (45)

1. Iacobellis G, Willens HJ. Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr 2009, 22:1311-1319. 10.1016/j.echo.2009.10.013, 19944955.
2. Jeong JW, Jeong MH, Yun KH, Oh SK, Park EM, Kim YK, Rhee SJ, Lee EM, Lee J, Yoo NJ, Kim NH, Park JC. Echocardiographic epicardial fat thickness and coronary artery disease. Circ J 2007, 71:536-539. 10.1253/circj.71.536, 17384455.
3. Iacobellis G, Ribaudo MC, Assael F, Vecci E, Tiberti C, Zappaterreno A, Di Mario U, Leonetti F. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab 2003, 88:5163-5168. 10.1210/jc.2003-030698, 14602744.
4. Baker AR, Silva NF, Quinn DW, Harte AL, Pagano D, Bonser RS, Kumar S, McTernan PG. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol 2006, 5:1. 10.1186/1475-2840-5-1, 1352345, 16412224.
5. Mathieu P, Pibarot P, Larose E, Poirier P, Marette A, Després JP. Visceral obesity and the heart. Int J Biochem Cell Biol 2008, 40:821-836. 10.1016/j.biocel.2007.12.001, 18201922.
6. Sicari R, Sironi AM, Petz R, Frassi F, Chubuchny V, De Marchi D, Positano V, Lombardi M, Picano E, Gastaldelli A. Pericardial rather than epicardial fat is a cardiometabolic risk marker: an MRI vs echo study. J Am Soc Echocardiogr 2011, 24(10):1156-1162. 10.1016/j.echo.2011.06.013, 21795020.
7. Sironi AM, Petz R, De Marchi D, Buzzigoli E, Ciociaro D, Positano V, Lombardi M, Ferrannini E, Gastaldelli A. Impact of increased visceral and cardiac fat on cardiometabolic risk and disease. Diabet Med 2012, 29(5):622-627. 10.1111/j.1464-5491.2011.03503.x, 22023514.
8. Konishi M, Sugiyama S, Sato Y, Oshima S, Sugamura K, Nozaki T, Ohba K, Matsubara J, Sumida H, Nagayoshi Y, Sakamoto K, Utsunomiya D, Awai K, Jinnouchi H, Matsuzawa Y, Yamashita Y, Asada Y, Kimura K, Umemura S, Ogawa H. Pericardial fat inflammation correlates with coronary artery disease. Atherosclerosis 2010, 213:649-655. 10.1016/j.atherosclerosis.2010.10.007, 21040916.
9. Nelson AJ, Worthley MI, Psaltis PJ, Carbone A, Dundon BK, Duncan RF, Piantadosi C, Lau DH, Sanders P, Wittert GA, Worthley SG. Validation of cardiovascular magnetic resonance assessment of pericardial adipose tissue volume. J Cardiovasc Magn Reson 2009, 5:11-15.
10. Rosito GA, Massaro JM, Hoffmann U, Ruberg FL, Mahabadi AA, Vasan RS, O'Donnell CJ, Fox CS. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation 2008, 117:605-613. 10.1161/CIRCULATIONAHA.107.743062, 18212276.
11. Hirata Y, Kurobe H, Akaike M, Chikugo F, Hori T, Bando Y, Nishio C, Higashida M, Nakaya Y, Kitagawa T, Sata M. Enhanced Inflammation in Epicardial Fat in Patients With Coronary Artery Disease. Int Heart J 2011, 52(3):139-142. 10.1536/ihj.52.139, 21646734.
12. Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol 2007, 157(5):545-559. 10.1530/EJE-07-0455, 17984234.
13. Desbriere R, Vuaroqueaux V, Achard V, Boullu-Ciocca S, Labuhn M, Dutour A, Grino M. 11β-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity 2006, 14:794-798. 10.1038/oby.2006.92, 16855188.
14. Engeli S, Böhnke J, Feldpausch M, Gorzelniak K, Heintze U, Janke J, Luft FC, Sharma AM. Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes Res 2004, 12:9-17. 10.1038/oby.2004.3, 14742837.
15. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM. 11β-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004, 25:831-866. 10.1210/er.2003-0031, 15466942.
16. Lindsay RS, Wake DJ, Nair S, Bunt J, Livingstone DEW, Permana PA, Tataranni PA, Walker BR. Subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab 2003, 88:2738-2744. 10.1210/jc.2002-030017, 12788882.
17. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001, 294:2166-2170. 10.1126/science.1066285, 11739957.
18. Rask E, Walker BR, Soderberg S, Livingstone DE, Eliasson M, Johnson O, Andrew R, Olsson T. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 2002, 87:3330-3336. 10.1210/jc.87.7.3330, 12107245.
19. Roberge C, Carpentier AC, Langlois MF, Baillargeon JP, Ardilouze JL, Maheux P, Gallo-Payet N. Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity. Am J Physiol Endocrinol Metab 2007, 293(6):E1465-E1478. 10.1152/ajpendo.00516.2007, 17911338.
20. Silaghi A, Silaghi H, Scridon T, Pais R, Achard V. Glucocorticoid receptors in human epicardial adipose tissue: role of coronary status. J Endocrinol Invest 2011, 35:649-654.
21. Onat A, Hergenc G, Can G. Prospective validation in identical Turkish cohort of two metabolic syndrome definitions for predicting cardiometabolic risk and selection of most appropriate definition. Anadolu Kardiyol Derg 2007, 7:29-34.
22. Onat A, Hergenc G, Türkmen S, Yazici M, Sari I, Can G. Discordance between insulin resistance and metabolic syndrome: features and associated cardiovascular risk in adults with normal glucose regulation. Metabolism 2006, 55:445-452. 10.1016/j.metabol.2005.10.005, 16546474.
23. Yazici Z, Tavares IA, Stamford IF, Bishai PM, Bennett A. Changes in tissue fatty acid composition in murine malignancy and following anticancer therapy. Br J Cancer 1992, 65(2):163-170. 10.1038/bjc.1992.35, 1977747, 1739611.
24. Hirata A, Maeda N, Nakatsuji H, Hiuge-Shimizu A, Okada T, Funahashi T, Shimomura I. Contribution of glucocorticoid-mineralocorticoid receptor pathway onthe obesity related adipocyte dysfunction. Biochem Biophys Res Commun 2012, 9;419(2)):182-187.
25. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, Mullins JJ. 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 1997, 94:14924-14929. 10.1073/pnas.94.26.14924, 25139, 9405715.
26. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ, Seckl JR. Novel adipose tissue mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004, 53:931-938. 10.2337/diabetes.53.4.931, 15047607.
27. Silaghi A, Achard V, Paulmyer-Lacroix O, Scridon T, Tassistro V, Duncea I, Clément K, Dutour A, Grino M. Expression of adrenomedullin in human epicardial adipose tissue: role of coronary status. Am J Physiol Endocrinol Metab 2007, 293:E1443-E1450. 10.1152/ajpendo.00273.2007, 17878224.
28. Lee MJ, Fried SK, Mundt SS, Wang Y, Sullivan S, Stefanni A, Daugherty BL, Hermanowski-Vosatka A. Depot-specific regulation of the conversion of cortisone to cortisol in human adipose tissue. Obesity 2008, 16:1178-1185. 10.1038/oby.2008.207, 18388900.
29. Veilleux A, Rhéaume C, Daris M, Luu-The V, Tchernof A. Omental adipose tissue type 1 11 beta-hydroxysteroid dehydrogenase oxoreductase activity, body fat distribution, and metabolic alterations in women. J Clin Endocrinol Metab 2009, 94:3550-3557. 10.1210/jc.2008-2011, 19567539.
30. Gormez S, Demirkan A, Atalar F, Caynak B, Erdim R, Sozer V, Gunay D, Akpinar B, Ozbek U, Buyukdevrim AS. Adipose tissue gene expression of adiponectin, tumor necrosis factor -α and leptin in metabolic syndrome patients with coronary artery disease. Intern Med 2011, 50(8):805-810. 10.2169/internalmedicine.50.4753, 21498926.
31. Zhou Y, Wei Y, Wang L, Wang X, Du X, Sun Z, Dong N, Chen X. Decreased adiponectin and increased inflammation expression in epicardial adipose tissue in coronary artery disease. Cardiovasc Diabetol 2011, 10(1):2. 10.1186/1475-2840-10-2, 3032658, 21226932.
32. Gao X, Mi S, Zhang F, Gong F, Lai Y, Gao F, Zhang X, Wang L, Tao H. Association of chemerin mRNA expression in human epicardial adipose tissue with coronary atherosclerosis. Cardiovasc Diabetol 2011, 10:87. 10.1186/1475-2840-10-87, 3198902, 21981776.
33. Schlett CL, Ferencik M, Kriegel MF, Bamberg F, Ghoshhajra BB, Joshi SB, Nagurney JT, Fox CS, Truong QA, Hoffmann U. Association of pericardial fat and coronary high-risk lesions as determined by cardiac CT. Atherosclerosis 2012, 222(1):129-134. 10.1016/j.atherosclerosis.2012.02.029, 22417843.
34. Fox CS, Gona P, Hoffmann U, Porter SA, Salton CJ, Massaro JM, Levy D, Larson MG, D'Agostino RB, O'Donnell CJ, Manning WJ. Pericardial fat, intrathoracic fat, and measures of left ventricular structure and function: the Framingham Heart Study. Circulation 2009, 119(12):1586-1591. 10.1161/CIRCULATIONAHA.108.828970, 2727456, 19289634.
35. Ahmadi N, Nabavi V, Yang E, Hajsadeghi F, Lakis M, Flores F, Zeb I, Bevinal M, Ebrahimi R, Budoff M. Increased epicardial, pericardial, and subcutaneous adipose tissue is associated with the presence and severity of coronary artery calcium. Acad Radiol 2010, 17(12):1518-1524. 10.1016/j.acra.2010.08.017, 20947390.
36. Park JS, Ahn SG, Hwang JW, Lim HS, Choi BJ, Choi SY, Yoon MH, Hwang GS, Tahk SJ, Shin JH. Impact of body mass index on the relationship of epicardial adipose tissue to metabolic syndrome and coronary artery disease in an Asian population. Cardiovasc Diabetol 2010, 9:29. 10.1186/1475-2840-9-29, 2913996, 20604967.
37. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006, 444(7121):860-867. 10.1038/nature05485, 17167474.
38. Odegaard JI, Chawla A. Mechanisms of macrophage activation in obesity-induced insulin resistance. Nat Clin Pract Endocrinol Metab 2008, 4(11):619-626. 10.1038/ncpendmet0976, 3381907, 18838972.
39. Baker AR, Harte AL, Howell N, Pritlove DC, Ranasinghe AM, da Silva NF, Youssef EM, Khunti K, Davies MJ, Bonser RS, Kumar S, Pagano D, McTernan PG. Epicardial adipose tissue as a source of nuclear factor-κB and c-Jun N-terminal kinase mediated inflammation in patients with coronary artery disease. JCEM 2009, 94:261-267.
40. Alessi M, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997, 46:860-867. 10.2337/diabetes.46.5.860, 9133556.
41. Walker BR. Cortisol cause and cure for metabolic syndrome. Diabet Med 2006, 23:1281-1288. 10.1111/j.1464-5491.2006.01998.x, 17116176.
42. Tomlinson JW, Sinha B, Bujalska I, Hewison M, Stewart PM. Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab 2002, 87:5630-5635. 10.1210/jc.2002-020687, 12466364.
43. Paulsen SK, Pedersen SB, Jørgensen JO, Fisker S, Christiansen JS, Flyvbjerg A, Richelsen B. Growth hormone (GH) substitution in GH-deficient patients inhibits 11beta-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression in adipose tissue. J Clin Endocrinol Metab 2006, 91:1093-1098.
44. Guauque-Olarte S, Gaudreault N, Piché M, Fournier D, Mauriège P, Mathieu P, Bossé Y. The transcriptome of human epicardial, mediastinal and subcutaneous adipose tissues in men with coronary artery disease. PLoS One 2011, 6(5):e19908. 10.1371/journal.pone.0019908, 3095619, 21603615.
45. Vara Prasad SS, Jeya Kumar SS, Kumar PU, Qadri SS, Vajreswari A. Dietary fatty acid composition alters 11β-hydroxysteroid dehydrogenase type 1 gene expression in rat retroperitoneal white adipose tissue. Lipids Health Dis 2010, 89:111.